Dolby Laboratories (DLB) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

CervoMed (CRVO) provided an update on its neflamapimod development program in dementia with Lewy bodies, DLB, as part of an oral presentation ...

Q1 2025 Earnings Call Transcript January 29, 2025 Dolby Laboratories, Inc. beats earnings expectations. Reported EPS is $1.14 ...

Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently ma ...

The headline numbers for Dolby Laboratories (DLB) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall ...

Barrington analyst Patrick Sholl maintained a Buy rating on Dolby Laboratories (DLB – Research Report) today and set a price target of $100.00.

Dolby Laboratories (NYSE:DLB) reported its financial results for the first quarter of 2025, surpassing earnings expectations ...

Here's a brief overview of the earnings report. Dolby Laboratories beat estimated earnings by 16.0%, reporting an EPS of $1.14 versus an estimate of $0.98. Revenue was up $41.42 million from the same ...

Dolby Laboratories beat estimated earnings by 16.0%, reporting an EPS of $1.14 versus an estimate of $0.98. Revenue was up ...

SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Dolby Laboratories Inc. (DLB) on Wednesday reported fiscal first-quarter earnings of $67.8 million. On a per-share basis, the San Francisco-based company said ...

Barrington Research restated their outperform rating on shares of Dolby Laboratories (NYSE:DLB – Free Report) in a research note published on Monday,Benzinga reports. The firm currently has a $100.00 ...